Shanghai Shyndec Pharmaceutical Crescita futura

Future criteri di controllo 1/6

Shanghai Shyndec Pharmaceutical prevede che gli utili e i ricavi cresceranno rispettivamente di 16% e 7.6% all'anno. Si prevede che l'EPS crescerà di 16.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 10.3% in 3 anni.

Informazioni chiave

16.0%

Tasso di crescita degli utili

16.3%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	18.7%
Tasso di crescita dei ricavi	7.6%
Rendimento futuro del capitale proprio	10.3%
Copertura analitica	Low
Ultimo aggiornamento	15 Nov 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching

Nov 17

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth

Oct 08

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Aug 23

Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified

May 06

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?

Apr 30

Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)

Apr 05

Previsioni di crescita degli utili e dei ricavi

SHSE:600420 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	13,705	1,557	N/A	2,784	2
12/31/2025	12,876	1,377	N/A	2,490	2
12/31/2024	12,024	1,173	N/A	2,217	1
9/30/2024	11,501	1,082	2,036	2,300	N/A
6/30/2024	11,585	1,065	2,332	2,626	N/A
3/31/2024	11,776	844	1,880	2,162	N/A
12/31/2023	12,070	692	1,363	1,720	N/A
9/30/2023	12,402	765	2,022	2,336	N/A
6/30/2023	13,017	748	2,186	2,500	N/A
3/31/2023	13,132	729	2,402	2,708	N/A
12/31/2022	12,959	628	2,548	2,856	N/A
9/30/2022	12,954	363	1,924	2,273	N/A
6/30/2022	12,700	367	2,115	2,503	N/A
3/31/2022	13,260	425	1,536	1,991	N/A
12/31/2021	13,945	568	1,158	1,680	N/A
9/30/2021	13,903	649	1,148	1,712	N/A
6/30/2021	13,977	748	966	1,524	N/A
3/31/2021	13,182	734	1,470	2,002	N/A
12/31/2020	12,556	649	1,182	1,560	N/A
9/30/2020	12,538	713	153	496	N/A
6/30/2020	12,156	611	-72	371	N/A
3/31/2020	12,328	607	293	685	N/A
12/31/2019	12,199	656	866	1,270	N/A
9/30/2019	11,860	703	2,418	2,839	N/A
6/30/2019	11,723	667	2,389	2,779	N/A
3/31/2019	11,386	717	1,270	1,669	N/A
12/31/2018	11,321	706	1,270	1,669	N/A
9/30/2018	10,416	647	2,220	2,530	N/A
6/30/2018	9,791	569	N/A	2,411	N/A
3/31/2018	9,260	530	N/A	2,565	N/A
12/31/2017	8,518	516	N/A	2,315	N/A
9/30/2017	9,086	539	N/A	1,050	N/A
6/30/2017	9,124	544	N/A	869	N/A
3/31/2017	9,324	534	N/A	654	N/A
12/31/2016	9,126	477	N/A	839	N/A
9/30/2016	13,514	773	N/A	1,898	N/A
6/30/2016	12,126	697	N/A	1,821	N/A
3/31/2016	10,388	580	N/A	1,912	N/A
12/31/2015	8,988	530	N/A	1,666	N/A
9/30/2015	2,829	206	N/A	254	N/A
6/30/2015	2,820	211	N/A	50	N/A
3/31/2015	2,882	203	N/A	202	N/A
12/31/2014	2,749	190	N/A	259	N/A
9/30/2014	2,492	169	N/A	292	N/A
6/30/2014	2,442	159	N/A	386	N/A
3/31/2014	2,317	137	N/A	129	N/A
12/31/2013	2,350	133	N/A	207	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 600420 ( 16% all'anno) è superiore al tasso di risparmio ( 2.8% ).

Guadagni vs Mercato: Si prevede che gli utili di 600420 ( 16% all'anno) cresceranno più lentamente rispetto al mercato CN ( 26.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 600420 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 600420 ( 7.6% all'anno) crescerà più lentamente rispetto al mercato CN ( 13.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 600420 ( 7.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 600420 sarà basso tra 3 anni ( 10.3 %).

Shanghai Shyndec Pharmaceutical Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Investor sentiment improves as stock rises 17%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)

Full year 2023 earnings: EPS exceeds analyst expectations

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.076 in 1Q 2022)

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in FY 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 1.199999999 billion in funding from China National Pharmaceutical Group Corporation

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.55 (vs CN¥0.63 in FY 2020)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.63 (vs CN¥0.62 in FY 2019)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.47

New 90-day low: CN¥9.01

New 90-day low: CN¥9.42

New 90-day high: CN¥10.68

Third quarter earnings released

New 90-day low: CN¥9.49

First half earnings released

New 90-day high - CN¥10.64

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita